Welcome to our dedicated page for Oric Pharmaceuticals news (Ticker: ORIC), a resource for investors and traders seeking the latest updates and insights on Oric Pharmaceuticals stock.
ORIC Pharmaceuticals, Inc. develops clinical-stage oncology therapies designed to counter mechanisms of therapeutic resistance in cancer. News about ORIC commonly covers rinzimetostat (ORIC-944), a selective allosteric PRC2/EED inhibitor studied in prostate cancer and metastatic castration-resistant prostate cancer, and enozertinib (ORIC-114), a brain-penetrant selective inhibitor targeting EGFR exon 20 insertion mutations and EGFR atypical mutations.
Recurring updates include clinical and preclinical data presentations, development-dose decisions, oncology conference presentations, quarterly financial results, cash runway disclosures, at-the-market equity financing, and Nasdaq Rule 5635(c)(4) inducement equity grants.
ORIC Pharmaceuticals reported its financial results for Q1 2021, highlighting progress in its oncology pipeline. The lead program, ORIC-101, is on track for Phase 1b data readouts in 2021, with two abstracts accepted for presentation at the ASCO Annual Meeting. The company anticipates filing INDs for ORIC-533, ORIC-944, and ORIC-114 within the year. Financially, cash and equivalents totaled $278.1 million, expected to fund operations through mid-2023. R&D expenses rose to $11.7 million, primarily due to advancements in product candidates, while G&A expenses increased to $4.9 million.
ORIC Pharmaceuticals announced that two abstracts featuring preliminary results from the Phase 1b study of ORIC-101 in combination with nab-paclitaxel are set for presentation at the 2021 ASCO Annual Meeting from June 4 - 8, 2021. The initial data will highlight the effects of ORIC-101, a glucocorticoid receptor antagonist, on patients with advanced solid tumors. The company plans to release data from a second trial involving enzalutamide later this year. These presentations aim to support ORIC's efforts in addressing therapeutic resistance in cancer treatments.
ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC) showcased four preclinical studies at the 2021 AACR virtual annual meeting, focusing on its innovative oncology treatments. Key highlights include ORIC-101's ability to overcome resistance in prostate cancer, ORIC-533's potential to reverse tumor immunosuppression, ORIC-944's superior efficacy in prostate cancer models, and ORIC-114's promising results in targeting EGFR and HER2 mutations.
These findings suggest significant progress in developing therapies that may enhance treatment effectiveness against resistant cancer types.
ORIC Pharmaceuticals reported significant advancements in its clinical operations for the year ended December 31, 2020. Their leading program, ORIC-101, is undergoing Phase 1b trials with anticipated interim data readouts slated for 2021. The company aims to file three IND/CTA applications for ORIC-533, ORIC-944, and ORIC-114, enhancing their development pipeline. As of December 31, 2020, cash and investments totaled $293.6 million, projected to sustain operations into the second half of 2023. However, R&D expenses rose significantly, indicating increased investment in pipeline development.
ORIC Pharmaceuticals, a clinical stage oncology company, announced four preclinical poster presentations at the 2021 AACR virtual annual meeting scheduled for April 10-15, 2021. The data focuses on ORIC's lead program ORIC-101 and three other candidates: ORIC-533, ORIC-944, and ORIC-114, which aim to address cancer resistance mechanisms. Each candidate shows potential best-in-class differentiation, with ORIC-101 reversing GR-mediated resistance in prostate cancer models. These advancements underscore ORIC's commitment to improving cancer treatment outcomes.
ORIC Pharmaceuticals, focused on overcoming cancer resistance, will present a company overview at two upcoming conferences. Jacob Chacko, M.D., CEO, will deliver an on-demand presentation at the H.C. Wainwright Global Life Sciences Conference on March 9, 2021, and a live presentation at the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021. Webcasts of both events will be accessible on the company’s website for 90 days. ORIC’s lead product, ORIC-101, targets glucocorticoid resistance in solid tumors and is currently in Phase 1b trials.
ORIC Pharmaceuticals, a clinical stage oncology company, announced participation in two investor conferences in February 2021. The Guggenheim Healthcare Talks 2021 Oncology Day features a virtual fireside chat on February 11 at 1:00 p.m. ET, while the LifeSci Partners Precision Oncology Day will host investor meetings on February 17. A live webcast of the fireside chat will be available on their website for 90 days post-event. ORIC focuses on developing therapies addressing cancer resistance mechanisms, with notable candidates including ORIC-101, ORIC-533, ORIC-944, and ORIC-114.
ORIC Pharmaceuticals (Nasdaq: ORIC) has outlined significant developments for 2021, focusing on clinical programs and pipeline expansion. Key highlights include the ongoing enrollment for ORIC-101 trials, with initial readouts anticipated this year. The company plans to submit three IND applications for ORIC-533, ORIC-944, and ORIC-114. Financially, ORIC reported $293.6 million in cash at the end of 2020, sufficient to fund operations into the second half of 2023. Jacob Chacko, CEO, emphasized these advancements position ORIC for a dynamic year ahead.
ORIC Pharmaceuticals, a clinical stage oncology company, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 12:40 p.m. PT. CEO Jacob Chacko will provide an overview of the company, which is focused on overcoming therapeutic resistance in cancer treatments. Their lead candidate, ORIC-101, is currently in Phase 1b trials for metastatic prostate cancer and advanced solid tumors in combination with Xtandi and Abraxane, respectively. A live webcast of the presentation will be available on their website.
ORIC Pharmaceuticals announced the initiation of Part II expansion of the Phase 1b study of ORIC-101, a glucocorticoid receptor antagonist, combined with Abraxane for treating advanced solid tumors. This stage will enroll up to 132 patients with pancreatic ductal adenocarcinoma, ovarian cancer, triple-negative breast cancer, and others. The recommended Phase 2 dose was found to be 160 mg of ORIC-101 with 75 mg/m² of Abraxane. The trial aims to address significant unmet medical needs in these cancer types.